Posted on 13 SEP 2011: Hershey, PA. Sept. 13. An official ribbon cutting ceremony marked the opening of vivoPharm’s new American facility, signifying a time of promising growth and new beginnings for the Australian-based contract research organization (CRO).
For nearly a decade, vivoPharm has successfully served the biotechnology and pharmaceutical industries from its facilities in Adelaide, Australia and Munich, Germany. Today, the organization is recognized as the fastest growing CRO in Australia with ambitious plans to triple in size over the next three years.
“We are proud to be the fastest growing CRO in Australia and plan to take what we have learned over the past eight years to help new clients in the United States.” Dr. Ralf Brandt, CEO and managing director of vivoPharm, said. “Our success comes from challenging the standards of industry norms by instilling three very basic, yet oftentimes challenging, building blocks into every engagement: trust, flexibility and transparency. When you join these principles with a commitment to delivering projects accurately and on time, you can break barriers into the next generation of preclinical research services.”
The organization plans to utilize its new space as a sounding board for building new business engagements and maintaining strong relationships with existing clients in the U.S.
Partnerships with like-minded, U.S.-based research organizations and academic institutions will give vivoPharm the necessary resources to utilize models that are closer to the clinic and more predictive than what is on the market today.
Among these partnerships, a strategic alliance with MPI Research announced earlier this month, complements vivoPharm’s more than 60 characterized cell lines and specialty oncology models with the oncology and molecular imaging programs developed by MPI Research.
A close working relationship with Penn State Hershey Medical Center, located adjacent to vivoPharm’s new facility at Hershey Center for Applied Research, will provide access to a full staff of researchers to help the organization meet demand during times of great growth.
“With a complete arsenal of new principles, state-of-the-art facilities, top scientists and research resources, we are committed to helping both large pharmaceutical companies and biotechnology startups fulfill peak demand,” Dr. Fernando Felquer, vivoPharm’s vice president of global commercial development, said. “As an organization, vivoPharm is in constant pursuit of the highest level of service, in keeping clients informed and engaged throughout the life cycle of any given project. We’re ready to put these principles and resources to work for new clients within the U.S.”
For more information, please contact Dr. Fernando Felquer, vice president of global commercial development, firstname.lastname@example.org.